A Limited Food Effect Study of Gabapentin 800 mg Tablets

This study has been completed.
Sponsor:
Information provided by:
Actavis Inc.
ClinicalTrials.gov Identifier:
NCT00865631
First received: March 17, 2009
Last updated: August 13, 2010
Last verified: August 2010

March 17, 2009
August 13, 2010
June 1999
June 1999   (final data collection date for primary outcome measure)
Rate and Extend of Absorption [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00865631 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Limited Food Effect Study of Gabapentin 800 mg Tablets
A Limited Food Effect Study of 800 mg Gabapentin Tablets Versus 400 mg Gabapentin Capsules

The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by Parke-Davis following a single oral dose (1 x 800 mg tablet) or (2 x 400 mg capsules) in healthy adult male volunteers under non-fasting conditions, and will compare the differences in plasma levels after dosing the test formulation with and without food.

Study Type: Interventional Study Design: Randomized, single-dose, three-way crossover under fed and fasting conditions

Official Title: A Limited Food Effect Study of 800 mg Gabapentin Tablets versus 400 mg Gabapentin Capsules

Further study details as provided by Actavis Elizabeth LLC:

Primary Outcome Measures:

Rate and Extend of Absorption

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: Gabapentin 800 mg tablets, single dose (1 tablet)
    A: Experimental Subjects received Purepac formulated products under fasting conditions
    Other Name: Gabapentin
  • Drug: NEURONTIN® 400 mg capsules, single dose (2 capsules)
    B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
    Other Name: Gabapentin
  • Drug: Gabapentin 800 mg tablets, single dose (1 tablet)
    A: Experimental Subjects received Purepac formulated products under non-fasting conditions
    Other Name: Gabapentin
  • Experimental: A
    Gabapentin 800 mg tablets, single dose (1 tablet)
    Interventions:
    • Drug: Gabapentin 800 mg tablets, single dose (1 tablet)
    • Drug: Gabapentin 800 mg tablets, single dose (1 tablet)
  • Active Comparator: B
    NEURONTIN® 400 mg capsules, single dose (2 capsules)
    Intervention: Drug: NEURONTIN® 400 mg capsules, single dose (2 capsules)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
June 1999
June 1999   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Screening Demographics: All volunteers selected for this study will be healthy men 18 to 45 years of age, inclusive, at the time of dosing. The weight range will not exceed ± 15% for height and body frame as per Desirable Weights for Men• 1983 Metropolitan Height and Weight Table.
  • Screening Procedures: Each volunteer will complete the screening process within 28 days prior to Period I dosing. Consent documents for both the screening evaluation and HIV antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures.
  • Screening will include general observations, physical examination, demographics, medical and medication history, an electrocardiogram, sitting blood pressure and heart rate, respiratory rate and temperature. The physical examination will include, but may not be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems.
  • The screening clinical laboratory procedures will include:

    • HEMATOLOGY: hematocrit, hemoglobin, WBC count with differential, RBC count, platelet count;
    • CLINICAL CHEMISTRY: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin, total bilirubin, total protein, and alkaline phosphatase;
    • HIV antibody and hepatitis B surface antigen screens;
    • URINALYSIS: pH, albumin, sugar, acetone, bilirubin, occult blood and microscopic analysis; and
    • URINE DRUG SCREEN: ethyl alcohol. amphetamines. barbiturates, benzodiazepines, cannabinoids. cocaine metabolites, opiates and phencyclidine.

Exclusion Criteria:

  • Volunteers with a recent history of drug or alcohol addiction or abuse.
  • Volunteers with the presence ofa clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the medical investigator).
  • Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
  • Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive HIV antibody screen.
  • Volunteers demonstrating a positive drug abuse screen when screened for this study.
  • Volunteers with a history of allergic response(s) to gabapentin or related drugs.
  • Volunteers with a history of clinically significant allergies including drug allergies.
  • Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the medical investigator.
  • Volunteers who currently use tobacco products.
  • Volunteers who have taken any drug known to induce or inhibit hepatic drug - Volunteers who report donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
  • Volunteers who have donated plasma (e.g. plasmaphoresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study.
  • Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing.
  • Volunteers who report taking any systemic prescription medication in the 14 days prior to Period I dosing.
Male
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00865631
P99-229
No
Meena Venugopal, Director, Clinical R&D, Actavis Inc
Actavis Inc.
Not Provided
Principal Investigator: James D. Carlson,, Pharm. D. PRACS Institute, Ltd.
Actavis Inc.
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP